title: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
abstract: A suggestive case of metastatic disease from breast cancer is reported. The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib. After re-induction of trastuzumab in combination with activated natural killer (NK) cell injection therapy, tumor markers decreased, and finally a synergistic effect of taxane and capecitabine led to treatment response. This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease.
authors.affiliation: Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Terunuma
authors.forename: Xuewen
authors.initials: X
authors.lastname: Deng
authors.forename: Md Zahidunnabi
authors.initials: MZ
authors.lastname: Dewan
authors.forename: Shigehira
authors.initials: S
authors.lastname: Saji
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Kuroi
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Masakazu
authors.initials: M
authors.lastname: Toi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D000069287:Capecitabine; D018270:Carcinoma, Ductal, Breast / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007694:Killer Cells, Natural / Q000637:transplantation*; D000077341:Lapatinib; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016879:Salvage Therapy; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C080625:taxane